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Abstract 17 
Study hypothesis: Steroid receptor coactivator interacting protein (SIP/KANK2) is involved in 18 
regulating the expression of the prostaglandin (PG)-endoperoxide synthase 2 (PTGS2; also known as 19 
cyclo-oxygenase 2, COX2) and PG release in human myometrium.   20 
Study finding: SIP is phosphorylated in myometrial cells in response to epidermal growth factor 21 
(EGF)-stimulation and is required for EGF-stimulated increases in COX2 expression, PGE2 and 22 
PGF2α release, and expression of interleukins (IL) 6 and IL8. 23 
What is known already: Human parturition involves inflammatory and non-inflammatory pathways 24 
and requires activation of the intrauterine PG cascade. A key mediator of uterine PG production is the 25 
highly inducible enzyme COX2. Regulation of COX2 expression is complex, and novel factors 26 
involved in its induction may play an important role during labour. The expression and function of 27 
SIP in uterine tissues has never been investigated. 28 
Study design, samples/materials, methods: Mass spectrometry was used to identify SIP from 29 
cultured primary myometrial cells, and its expression in fresh placenta, fetal membranes, decidua and 30 
myometrium from pregnant and non-pregnant women was determined by western blotting.  SIP 31 
expression in myometrial cells was reduced using small interfering RNA (siRNA), and COX2 32 
expression was stimulated with EGF. COX2, IL6 and IL8 mRNA and COX2 protein expression were 33 
measured using quantitative RT-PCR (RT-qPCR) and western blotting respectively, and release of 34 
PGE2 and PGF2α by enzyme immunoassay. The time course and dose response of SIP phosphorylation 35 
in response to EGF were determined, and phosphorylation was measured in the presence of the 36 
mitogen-activated protein kinase kinase 1(MEK1) inhibitor PD-184352. Fresh myometrial tissue was 37 
used to confirm effects of EGF and MEK1 inhibition on SIP phosphorylation and COX2 expression. 38 
A profile of transcription factor (TF) activity after SIP knockdown was carried out using a 39 
commercially available array.  40 
Main results and the role of chance: We have demonstrated expression of SIP in human 41 
myometrium.  siRNA-mediated knockdown of SIP resulted in decreased EGF-stimulated COX2 42 
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protein expression (P < 0.001), and decreased release of PGE2 (P < 0.001) and PGF2α (P < 0.01) . 43 
EGF stimulation resulted in rapid and transient phosphorylation of SIP, which was blocked by 44 
pharmacological inhibition of the MEK1/ERK (extracellular signal-regulated kinase) signalling 45 
pathway with PD-184352 (P < 0.001). Moreover inhibition of ERK signalling significantly decreased 46 
EGF-stimulated COX2 expression (P < 0.001). EGF phosphorylated SIP and increased COX2 47 
expression in a MEK1/ERK-dependent manner in freshly isolated pregnant myometrium. Our data 48 
have uncovered a pathway mediating EGF-stimulated COX2 expression that is ERK and SIP 49 
dependent, providing a novel function for SIP in the pregnant uterus. Furthermore, EGF stimulated 50 
the expression of IL6 and IL8 mRNA in a SIP-dependent manner (both P < 0.05), and SIP expression 51 
was positively associated with activation of serum response factor (SRF) and YY1 TF (P < 0.001 and 52 
P < 0.05 respectively), suggesting additional important roles for myometrial SIP. 53 
Limitations, reasons for caution: While we describe a new role for myometrial SIP, we are yet to 54 
determine whether SIP phosphorylation is required for its effects on regulating COX2 expression and 55 
PG release. Our data are from in vitro studies using fresh tissue and cultured myometrial cells and 56 
may not fully reflect the conditions in vivo. 57 
Wider implications of the findings: Our group has previously described increases in myometrial 58 
COX2 expression with labour at term and preterm. EGF levels rise in the amniotic fluid near term 59 
suggesting it may participate in paracrine signalling events, altering gene expression in the 60 
myometrium. Our novel data describe a role for SIP in regulating EGF-stimulated expression of 61 
myometrial COX2 and PG release. Moreover, our profile of SIP-dependent TF activation provides a 62 
platform for further investigations into additional roles for SIP in uterine function. These findings may 63 
facilitate the development of new, targeted drugs for the management of labour.  64 
Large scale data: Not applicable. 65 
Study funding and competing interest(s): This work was supported by an Action Medical Research 66 
grant (SP4612). The authors have no competing interests to declare. 67 
 68 
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Introduction 75 
Inflammatory responses are an important component of parturition at term and preterm. They involve 76 
activation of the intrauterine prostaglandin (PG) cascade, leading to increased uterine PG production 77 
at labour. This can be measured as increasing PG levels in amniotic fluid with progressive cervical 78 
dilation (Keirse, 1978), and an increase in PG metabolites in maternal serum (Sellers et al. , 1982). 79 
PGs facilitate concerted cervical ripening, fetal membrane rupture, and the development of 80 
myometrial contractions. Consequently, PGs have been used successfully for clinical induction of 81 
labour and PG inhibitors for the treatment of preterm labour (Haas et al. , 2012, Kaminski et al. , 82 
1994). Prostaglandin-endoperoxide synthases 1 and 2 (PTGS1 and 2), also known as cyclo-83 
oxygenases 1 and 2 (COX1 and 2) are rate-limiting enzymes for PG synthesis. They convert 84 
arachidonic acid to prostaglandin endoperoxides, which are further converted into a variety of PGs by 85 
cell-specific terminal synthases. COX2 is a highly inducible enzyme; in human myometrium COX2 is 86 
upregulated in late pregnancy and with labour (Erkinheimo et al. , 2000, Phillips et al. , 2011, Slater 87 
et al. , 1999b) whereas COX1 and the terminal PG synthases including PTGDS, PTGES and PGF 88 
synthase (AKR1B1) are constitutively expressed (Phillips et al., 2011),  hence COX2 is considered a 89 
key regulator of PG synthesis during pregnancy and labour.  COX2 gene and protein expression in 90 
human fetal membranes has been shown to increase during gestation and labour (Slater et al. , 1999a), 91 
while other studies show an increase in COX2 with gestational age at delivery, without a significant 92 
increase with labour in women (Phillips et al. , 2014). These increases are thought to be the cause 93 
rather than the effect of labour, as increases in COX2 expression (Slater et al., 1999a, Slater et al., 94 
1999b) and amniotic fluid PGF2α levels (Lee et al. , 2009) precede labour in women.  Expression of 95 
COX2 and PG release are further increased in human placenta and fetal membranes in cases of 96 
inflammatory infiltration (Lopez Bernal et al. , 1989, Phillips et al., 2014), and amniotic fluid levels 97 
of PGE2 and PGF2α increase during preterm labour with underlying intra-amniotic infection (Romero 98 
et al. , 1987). Uterine COX2 expression can be stimulated by mechanical stretch and by a variety of 99 
agonists including pro-inflammatory cytokines e.g. interleukin (IL) 1B and tumor necrosis factor 100 
(TNF), oxytocin (OXT), epidermal growth factor (EGF) and PGs themselves (Ackerman et al. , 2004, 101 
Chen et al. , 2012, Mohan et al. , 2007, Molnar et al. , 1999, Phillips et al., 2011, Sooranna et al. , 102 
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2004, Wouters et al. , 2014). The signalling pathways mediating agonist-induced increases in COX2 103 
in the late pregnant uterus are complex and not fully elucidated.  The COX2 gene promotor contains 104 
binding sites for several TFs including nuclear factor kappa B (NFKB), specificity protein 1 (SP1), 105 
CCAAT/enhancer-binding protein beta (CEBPB), cAMP response element binding protein (CREB) 106 
and peroxisome proliferator-activated receptor gamma (PPARG) (Kang et al. , 2007). NFKB activity 107 
is important for cytokine-induced increases in COX2, whereas OXT, EGF and PGs signal 108 
predominantly through extracellular signal-regulated kinase 1/2 (ERK1/2), protein kinase C (PKC) 109 
isoforms or nuclear factor of activated T-cells (NFAT) (Ackerman et al., 2004, Chen et al., 2012, 110 
Molnar et al., 1999, Pont et al. , 2012, Wouters et al., 2014).  111 
 112 
Steroid receptor coactivator (SRC) interacting protein (SIP or KANK2/ ANKRD25) is part of the 113 
KANK protein family whose members are characterised by a N-terminal KN motif, coiled-coil 114 
domains and C-terminal ankyrin repeat domains (Kakinuma et al. , 2009). All family members are 115 
thought to regulate actin polymerisation, as overexpression of each disrupts stress fibre formation 116 
(Zhu et al. , 2008). Akt-dependent phosphorylation of KANK1 results in binding of 14-3-3 proteins 117 
and negative regulation of RhoA-dependent actin polymerisation (Kakinuma et al. , 2008). In rat 118 
kidney, SIP (KANK2) binds Rho GDP-dissociation inhibitor (RhoGDI) which determines its ability 119 
to regulate RhoA-GTP levels (Gee et al. , 2015). There is evidence that SIP plays an alternative role 120 
in regulating estrogen-mediated transcription in MCF-7 cells. SIP functions by binding and 121 
sequestering SRC proteins in the cytoplasm, a process that requires Ca2+ /calmodulin-dependent 122 
protein kinase II (CAMK2)-dependent phosphorylation of SIP (Zhang et al. , 2007). Furthermore, 123 
mutations in the ankyrin repeat domain relieve cytoplasmic sequestration of SRC proteins and result 124 
in increased vitamin D receptor activity and keratoderma (Ramot et al., 2014). An additional role for 125 
SIP is regulation of apoptosis through binding to apoptosis-inducing factor in the mitochondria (Wang 126 
et al. , 2012).   127 
 128 
Here we report identification of SIP through mass spectrometry as a myometrial protein that is 129 
phosphorylated by EGF.  We assessed possible functions for SIP in human pregnant myometrium, 130 
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and found that SIP is required for EGF-stimulated expression of COX2, IL6 and IL8, and EGF-131 
stimulated release of PGE2 and PGF2α. EGF-mediated effects on SIP phosphorylation and COX2 132 
induction are dependent on ERK1/2.  133 
 134 
 135 
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Materials and methods 136 
Ethical approval and tissue collection. 137 
This study was approved by the North Somerset and South Bristol Research Ethics Committee 138 
(reference E5431) and all women gave informed written consent. Placenta and fetal membranes were 139 
collected immediately post-partum from term (≥ 37 weeks gestation) not-in-labour (TNIL) women, 140 
delivery by elective caesarean section indicated by previous section and/or breech presentation. 141 
Myometrium was collected from the following additional groups of women: preterm (28–36 weeks 142 
gestation) not-in-labour (PNIL), delivery by caesarean section for maternal or fetal complications; 143 
term following induction of labour (IOL) with intravaginal PGE2 pessary and/or i.v. OXT infusion 144 
with caesarean section; and non-pregnant (NP) taken at hysterectomy in premenopausal women. The 145 
tissue was washed in ice-cold isotonic saline and transported to the laboratory where it was used to 146 
prepare tissue lysates, tissue explants or freshly dispersed myometrial cells. 147 
Materials. 148 
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The following chemicals and reagents were obtained from the indicated sources: ON-TARGET plus 149 
non-targeting pool small interfering RNA (siRNA) and Dharmafect 1 transfection reagent were 150 
purchased from Abgene (Epsom, UK). siRNAs targeting SIP were designed and purchased from 151 
Eurofins (London, UK) and Invitrogen, Life Technologies (Stealth Select RNAi™ , Paisley, UK). 152 
Collagenase type II, dispase, Dulbecco’s modified Eagle’s medium (DMEM) and fetal calf serum 153 
(FCS) were purchased from Invitrogen, Life Technologies (Paisley, UK); elastase, DNAse, and OXT 154 
were purchased from Sigma Aldrich (Poole, UK).  Forskolin (FSK) and EGF were purchased from 155 
Merck (Nottingham, UK). MEK1 inhibitor PD-184532 was purchased from R&D systems (Abingdon, 156 
UK). Myosin light chain kinase (MYLK) (# ab76092), SIP (ANKRD25, # ab99351), glyceraldehyde-157 
3-phosphate dehydrogenase (GAPDH, # ab181602) and COX2 (# ab52237) antibodies were 158 
purchased from Abcam (Cambridge, UK); phosphorylated ERK (pERK)1/2 (# 4377) and ERK1/2 (# 159 
9102) antibodies were purchased from New England Biolabs (Hitchin, UK); RhoGDI antibody (sc-160 
360) and normal rabbit immunoglobulin (Ig)G (sc-2027) were purchased from Santa Cruz 161 
Biotechnology (Heidelberg, Germany). An antibody marketed for detection of phosphorylated MYLK 162 
(# 44-1085G) but found actually to recognise phospho-SIP (see Results), was purchased from Life 163 
Technologies (Paisley, UK). All other basic chemicals were supplied by Sigma Aldrich (Poole, UK) 164 
unless otherwise stated. 165 
 166 
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Myometrial cell culture and stimulation. 167 
Myometrial tissue was digested in serum-free DMEM containing 300 U/ml collagenase (type II), 0.3 168 
U/ml dispase, 30 U/ml DNase I and 0.09 U/ml elastase at 37 °C for 3 hours. Liberated smooth muscle 169 
cells were then grown in adherent cell culture with DMEM containing 10 % FCS, 100 U/ml penicillin 170 
and 100 µg/ml streptomycin at 37 °C. Experiments were carried out by plating cells of passage seven 171 
or lower at 2.8x105 per cm3 in 12-well plates and growing to confluency over 3 days.  For 172 
phosphorylation experiments, cells were serum-starved for 4 hours prior to experiments, pre-treated 173 
for 30 mins with MEK1 inhibitor where appropriate (PD-184352, 10 μM) followed by stimulation 174 
(typically with EGF, 25 ng/ml, 15 mins).  For COX2 expression, cells were incubated in phenol red-175 
free and serum-free media for 24 hours in the presence or absence of stimulation (typically 25 ng/ml 176 
EGF).  In both cases, cells were washed with phosphate-buffered saline (PBS), lysed directly in 177 
boiling sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (25 178 
mM Tris pH 6.8, 10 % glycerol, 2 % SDS, 12.5 mM dithiothreitol (DTT) and 0.002 % bromophenol 179 
blue), and used for immunoblotting as described below.   180 
 181 
Immunoprecipitation with pMYLK (44-1085G) and SIP antibodies. 182 
Myometrial cells grown to confluency in 10 cm dishes were serum-starved for 4 hours and then 183 
treated with or without 10 µM FSK or 25 ng/ml EGF for 15 min.  184 
For pMYLK immunoprecipitates (IPs): Cells were lysed on ice with 350 μl Triton buffer (20 mM 185 
Tris-HCl pH 8.2, 400 mM NaCl, 0.5 % Triton X-100, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM DTT, 1x 186 
protease (cOmplete) and phosphatase (PhosTOP) inhibitor mix (Roche Diagnositics Ltd, Burgess Hill, 187 
UK). Lysates were cleared by centrifugation at 16,000 g for 15 minutes at 4 ˚C and supernatants 188 
diluted 1:3 in dilution buffer (20 mM Tris-HCl pH 7.5, 0.5 % Triton X-100, 0.5 mM EDTA, 1 mM 189 
DTT and 1x protease and phosphatase inhibitor mix as above). Protein concentration was determined 190 
using the BCA assay kit (Perbio Science UK, Cramlington, UK), and approximately 0.5ml of lysate at 191 
1mg/ml was used per IP. Lysates were pre-cleared with protein A and protein G and then incubated 192 
with 6 µl/ml anti-phospho-MYLK (Ser1760, 44-1085G) antibody for 2 hours at 4 ˚C with rotation.  193 
Immune complexes were captured with 50 µl of each 50 % (v/v) protein A and 50 % (v/v) protein G 194 
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for 2 hours at 4 ˚C with rotation. IPs were washed 4 x 1 ml with wash buffer (20 mM Tri-HCl pH 7.7, 195 
0.5 % Triton X-100, 100 mM NaCl, 0.5 mM EDTA, 0.125 mM EGTA and 1 mM DTT) and eluted in 196 
SDS-sample buffer (25 mM Tris pH 6.8, 10 % glycerol, 2 % SDS, 12.5 mM DTT and 0.002 % 197 
bromophenol blue).  44-1085G IPs were run on 4-12 % NuPAGE Bis-Tris precast gels (Invitrogen 198 
Life Technologies, Paisley, UK) which were used for a combination of immunoblotting with the 44-199 
1085G antibody and silver staining to visualise proteins (SilverQuest kit, Invitrogen Life 200 
Technologies, Paisley, UK).  Following overlay of the 44-1085G immunoblot with the silver-stained 201 
picking gel, a gel slice was excised which corresponded to the ~ 100kDa band on the 44-1085G blot.  202 
For SIP IPs: Cells were lysed on ice in 1 ml SIP IP buffer (20 mM Hepes pH 7.8, 150 mM NaCl, 1 % 203 
Triton X-100, 1 mM EDTA, 1 mM EGTA, 1x protease and phosphatase inhibitors as above). Lysates 204 
were cleared by centrifugation at 16,000 g for 15 minutes at 4 ˚C and protein concentration was 205 
determined using the BCA assay kit and adjusted to 1 mg/ml using SIP IP buffer. Lysates were pre-206 
cleared with protein A and protein G before being divided into 2 x 0.5 ml (500 µg) samples and 207 
incubated with either 4 µg of anti-SIP antibody or 4 µg of normal rabbit IgG (control IP) for 2 hours 208 
at 4 ˚C with rotation.  Immune complexes were captured with 50 µl of each 50 % (v/v) protein A and 209 
50 % (v/v) protein G for 2 hours at 4 ˚C with rotation. IPs were washed 4 x 1 ml with SIP IP buffer 210 
and eluted in SDS-sample buffer as above. SIP and control IPs were loaded onto 10% SDS 211 
polyacrylamide gels and separation allowed to proceed until the dye front had moved 1cm into the 212 
separating gel.  Each gel lane was then excised and subjected to in-gel digestion and liquid 213 
chromatography mass spectrometry (LC-MS) as described below.  214 
 215 
Mass spectrometry of isolated ‘pMYLK’ band and SIP IPs  216 
The gel slices were subjected to in-gel tryptic digestion using a DigestPro automated digestion unit 217 
(Intavis Ltd, Nottingham, UK).  The resulting peptides were fractionated using an Ultimate 3000 218 
nanoHPLC system (Thermo Scientific, Loughborough, UK).  In brief, peptides in 1% (v/v) formic 219 
acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After 220 
washing with 0.5% (v/v) acetonitrile/0.1% (v/v) formic acid, peptides were resolved on a 250 mm × 221 
75 μm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over a 150 min 222 
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organic gradient with a flow rate of 300 nl/min. Peptides were ionized by nano-electrospray ionization 223 
at 2.1 kV using a stainless steel emitter with an internal diameter of 30 μm (Thermo Scientific). 224 
Tandem mass spectrometry analysis (MS/MS) was carried out on a LTQ-Orbitrap Velos mass 225 
spectrometer (Thermo Scientific).  The Orbitrap was set to analyse the survey scans at 60,000 226 
resolution and the top twenty multiply charged ions in each duty cycle were selected for MS/MS in 227 
the linear ion trap.  Data was acquired using the Xcalibar v2.1 software (Thermo Scientific). The raw 228 
data files from the 44-1085G IPs and the SIP IPs were processed using Proteome Discoverer software 229 
v1.2 or v1.4 respectively (Thermo Scientific) with searches performed against the UniProt Human 230 
database using the SEQUEST algorithm with the following criteria; percursor tolerance = 10 ppm, 231 
fragment tolerance = 0.8 Da, trypsin as the enzyme, carbamidomethylation of cysteine as a fixed 232 
modification and oxidation of methionine and phosphorylation of serine, threonine and tyrosine as 233 
variable modifications.  The reverse database search option was enabled and all peptide data were 234 
filtered to satisfy a false discovery rate of 5%. 235 
 236 
Knockdown of SIP with targeted siRNA. 237 
Myometrial cells grown to 50 % confluency in 12-well plates overnight in DMEM + 10 % FCS (no 238 
penicillin or streptomycin) were incubated in the presence of 25 nM siRNA:SIP1, 5’-239 
GACUGUCCUUCAGCUCUUC-3’; SIP2, 5’-CGTCCATATGGTGAAGAAG-3’, a combination of 240 
both SIPs or non-targeting (SCR) and 3 % (v/v) Dharmafect 1 reagent for 72 hours.  Cells were 241 
stimulated and lysed as above and protein knockdown verified by immunoblotting for SIP. 242 
Alternatively cells were grown for isolation of mRNA as described below.  243 
 244 
mRNA isolation and quantitative PCR analysis. 245 
RNA was isolated using an RNeasy mini kit (QIAGEN, West Sussex, UK) according to the 246 
manufacturer’s protocol; cells were lysed in RTL buffer containing 1 % β-mercaptoethanol. Quantity 247 
and quality of RNA was assessed by the NanoDrop 1000 full spectrum 220/750-nm 248 
spectrophotometer (Labtech International, East Sussex, UK). cDNA was synthesized from 1 µg RNA 249 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies, 250 
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Paisley, UK) following the manufacturer’s instructions and diluted 5-fold on reaction completion. 251 
Gene expression was quantified by real-time quantitative PCR (RT-qPCR) with Power SYBR Green 252 
Master Mix (Applied Biosystems, Life Technologies, Paisley, UK), using a 7500 real-time PCR 253 
system (Applied Biosystems, Life Technologies, Paisley, UK). A template of 2 µl cDNA was run per 254 
reaction in a final reaction volume of 20 µl (75 nM each forward and reverse primer, Table I) for 45 255 
cycles of 95 ˚C for 15 sec and 60 ˚C for 60 sec. A dissociation stage followed to ensure the 256 
amplification of a single product. Relative mRNA expression levels were quantified by the Pfaffl 257 
method of relative quantification (Pfaffl, 2001) and standardized to 18S (RNA18S5) and RNA 258 
polymerase II (POLR2A) levels. Expression levels were normalized to control values (SCR, non-259 
stimulated) for graphical representation and statistical analysis. 260 
SDS-PAGE, immunoblotting and quantification of immuno bands. 261 
Cell or tissue lysates (15 μg or 50 μg protein, respectively) were resolved using 7.5 % Bis-Tris gels 262 
(357 mM Bis-Tris pH 6.75, 8.5 % acrylamide, 0.23 % bis-acrylamide) and MOPS running buffer (250 263 
mM MOPS, 250 mM Tris, 5 mM EDTA, 0.5 % SDS).  Proteins were transferred to polyvinylidene 264 
diflouride membrane (GE Healthcare, Buckinghamshire, UK) by wet transfer at 250 mA for 1 hour in 265 
a buffer containing 25 mM Tris, 192 mM glycine, 10 % methanol and 0.01 % SDS.  Membranes were 266 
blocked in 5 % bovine serum albumin (BSA) in Tris-buffered saline + 0.1% Tween-20 (TBS-T), 267 
before incubation with primary antibodies (1 μg/ml in 5 % BSA/TBS-T) overnight at 4 °C.  After 268 
washing 6 x 5 minutes in TBS-T, membranes were incubated with a horseradish peroxidase (HRP)-269 
conjugated goat anti-rabbit antibody (#7074, 1:5000; New England Biolabs, Hitchin, UK) in TBS-T 270 
for 1 hour at room temperature.  Membranes were washed for a further 6 x 5 minutes and bands 271 
visualised using an enhanced chemiluminescence system (GE Healthcare, Buckinghamshire, UK).  272 
Membranes were probed initially with phospho-specific antibodies and re-probed with the equivalent 273 
total antibody after incubating for 3 x 1 hour in stripping buffer (20 mM glycine, 1 % SDS, pH 2).  274 
Bands were quantified by densitometry using Quantity One software (Bio-Rad, Hemel Hempstead, 275 
UK), and care was taken to avoid saturation of signals.  Raw data were normalised using an 276 
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experimental control for each experiment as detailed in individual figure legends, and the level of 277 
phosphorylation was always normalised using the level of equivalent total protein.   278 
Measurement of PG release. 279 
Primary myometrial cells were transfected with siRNA and switched to phenol red-free and serum-280 
free medium for a total of 24 h, with EGF stimulation for 4, 8 or 24 h. Media was collected and stored 281 
at -80 °C until use. PGs were measured using the PGE metabolite enzyme-linked immunosorbent 282 
assay (ELISA) kit and the PGF2α ELISA kit (Cayman Chemicals, MI, USA) using non-diluted media 283 
according to manufacturers’ instructions.  284 
Stimulation of myometrial explant tissue. 285 
Freshly obtained myometrium was rinsed in sterile PBS under laminar flow and dissected into small 286 
pieces (2 mm x 2 mm) within a 100 mm tissue culture dish using a sterile scalpel. Four pieces were 287 
placed in each well of a 12-well tissue culture plate and incubated in phenol red-free DMEM + 0.5 % 288 
FCS for 4 hours. Media was replaced and explants were pre-incubated with PD-184352 (10 µM) or 289 
0.1 % dimethylsulphoxide vehicle for 30 minutes followed by stimulation with 50 ng/ml EGF for 15 290 
minutes or 24 hours. Individual explants were rinsed in cold PBS following stimulation, snap frozen 291 
in liquid nitrogen, and stored at -80 °C before homogenisation. 292 
Tissue homogenisation. 293 
For SDS-PAGE, frozen tissue explants were homogenised in SDS buffer (25 mM Tris pH 6.8, 2 % 294 
SDS, 10 % glycerol) at approximately 100mg wet weight/ml using a Polytron homogeniser at 20 °C.  295 
Lysates were immediately heated to 95 °C for 5 minutes, and cleared by centrifugation at 16,000 g for 296 
10 minutes at 20 °C.   Protein concentration was determined using the BCA assay kit (Perbio Science 297 
UK, Cramlington, UK) before 12.5 mM DTT and 0.002 % bromophenol blue were added prior to 298 
electrophoresis. 299 
TF activation array. 300 
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The Signosis TF activation profiling array I (Stratech, Newmarket, UK) was used to determine the 301 
activity of 48 TFs following the manufacturer’s instructions. Briefly, nuclear extracts from 302 
myometrial cells grown in 6 cm dishes were produced using the Nuclear Extraction Kit from Signosis. 303 
Nuclear protein (10 µg) was combined with biotin-labelled probes based on the consensus DNA 304 
binding sites for 48 TFs. After column purification, bound probes were hybridised to a 96-well plate, 305 
each well specifically pre-coated with a complementary sequence to a specific probe. After washing 306 
and incubation with strepdavidin-HRP, luminescence was measured 10 min after substrate addition 307 
for a duration of 1 s.  308 
Statistical analyses. 309 
Data were analysed using GraphPad Prism, version 4.3 (GraphPad, San Diego, CA, USA). The 310 
comparisons between SIP expression in uterine tissues and pregnancy were performed using one-way 311 
analysis of variance (ANOVA) with Bonferroni post hoc tests. To verify siRNA-mediated knockdown 312 
of SIP mRNA and protein, paired Student's T tests were performed. The effects of EGF-stimulation 313 
with SIP siRNA or PD-184352 treatment on COX2, IL6 and IL8 expression and phosphorylation of 314 
SIP were determined using two-way ANOVA and Bonferroni post-hoc tests.  The effect of SIP 315 
siRNA on the time course of EGF-mediated PG release was determined by two-way ANOVA with 316 
repeated measures. Time course and dose-response data for SIP phosphorylation were analysed using 317 
repeated-measures ANOVA and Dunnett’s post-hoc tests. Individual TF activities in SIP knockdown 318 
cells were analysed using one sample t tests against a constant of 1. A P-value of < 0.05 was 319 
considered significant for all analyses. 320 
 321 
 322 
Results 323 
Antibody 44-1085G detects phospho-SIP in human myometrial cells. 324 
We used a commercially available antibody raised against phosphorylated MYLK to study MYLK 325 
phosphorylation under the influence of cyclic AMP as part of our studies on the regulation of 326 
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myometrial contractility. Using non-stimulated and FSK-treated myometrial whole cell lysates, this 327 
antibody (44-1085G) detected several bands by immunoblotting; the most reproducible and strong 328 
band was seen at approximately 100 kDa after FSK treatment (band 3, Supplementary Figure 1A).  329 
Additional bands could be seen at > 250 kDa in FSK-treated cell lysates (band 1) and at 145 kDa in 330 
both non-stimulated and stimulated conditions (band 2). Immunoblots re-probed with a MYLK 331 
antibody showed expression of the 210 kD and 110 kDa MYLK isoforms as expected (bands 4 and 5 332 
respectively, Supplementary Figure 1B), however these did not correspond to any of the bands on the 333 
44-1085G blot.  The main ‘pMYLK’ band seen consistently in FSK-treated cell lysates (~ 100 kDa) 334 
was smaller than MYLK, and could easily be separated from the MYLK band using 7.5% acrylamide 335 
gels. We carried out immunoprecipitation using the 44-1085G antibody, and demonstrated by 336 
immunoblotting that MYLK was absent from these IPs; we had isolated the 100 kDa band 337 
independently of MYLK (Supplementary Figure 1A and B). To isolate this protein we cut a gel slice 338 
corresponding to the 100 kDa band by aligning the pMYLK blot with an equivalent picking gel 339 
(Supplementary Figure 1C). Tandem MS analysis of this band revealed it to be SIP (or KANK2), and 340 
several phosphorylation sites were identified in the FSK-treated IPs (Supplementary Tables I and II).  341 
 342 
Verification of SIP phosphorylation in human myometrial cells. 343 
A commercially available SIP antibody was used to verify the presence of SIP protein in primary 344 
myometrial cells by immunoblotting, and we were able to successfully reduce the expression of SIP 345 
protein using siRNA (Figure 1, top panel). A band of approximately 100 kDa detected using the 44-346 
1085G antibody was increased by EGF and FSK but not by OXT or carbachol (Figure 1). The 347 
increase in response to EGF and FSK was decreased after reduction of SIP protein levels by siRNA. 348 
Moreover, the ~100 kDa band on the 44-1085G blot and the SIP band overlaid exactly. To study 349 
EGF-induced phosphorylation of SIP, the SIP antibody was used for immunoprecipitation using non- 350 
and EGF-stimulated cell lysates. Whole IPs were subjected to tandem MS and two SIP phospho-351 
peptides were identified in EGF-stimulated IPs which were absent in non-stimulated IPs 352 
(Supplementary table III), which correspond to serine 323 and serine 375 of SIP.  Taken together, our 353 
data show that the ~100 kDa band detected by antibody 44-1085G is actually SIP (in spite of the fact 354 
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that it is marketed for detection of pMYLK), EGF stimulation increases immunoreactivity of this band 355 
and concomitantly increases phosphorylation of SIP at two sites, suggesting this antibody is detecting 356 
phosphorylated SIP. The ~100 kDa band will be referred to as pSIP from this point on. 357 
 358 
SIP is expressed in fresh human myometrium and fetal membranes. 359 
After identification of SIP as a phospho-protein in cultured myometrial cells, the expression of SIP in 360 
fresh myometrium was verified and compared to the levels in other uterine tissues from TNIL women. 361 
SIP was detected by immunoblotting and expression was high in myometrium and in fetal membranes 362 
(combined amnion, chorion and decidua parietalis), but low in placenta and decidua basalis (Figure 363 
2).  SIP expression was subsequently studied in NP myometrium and compared to pregnant 364 
myometrium from TNIL and PNIL groups. Tissue from IOL women was also compared. SIP protein 365 
expression was significantly downregulated in pregnancy (P < 0.05), while there was no difference 366 
among the PNIL, TNIL and IOL groups (Figure 3). 367 
 368 
SIP removal inhibits expression of the COX-2 gene. 369 
SIP is involved in regulating steroid hormone-dependent transcription in a breast cancer cell line 370 
(Zhang et al., 2007) and we screened several potential estrogen- or progesterone-regulated 371 
myometrial genes and steroid receptor coactivators for changes in expression in SIP siRNA-treated 372 
human myometrial cells. Knockdown of SIP mRNA by 71.9 ± 4.8 % (mean ± SEM; P < 0.01, n= 3) 373 
was associated with a decrease in the expression of COX2 mRNA (by 34.7 ± 7.8 %, data not shown) 374 
with no appreciable effect on another 10 genes studied (PGR, progesterone receptor; ESR2, estrogen 375 
receptor 2; OXTR, oxytocin receptor; COX1, prostaglandin-endoperoxide synthase 1; PTGFR, 376 
prostaglandin F receptor; PTGER2, prostaglandin E receptor 2; PTGER3, prostaglandin E receptor 3; 377 
PTGES, prostaglandin E synthase; NCOA1, nuclear receptor coactivator 1 and NCOA2, nuclear 378 
receptor coactivator 2; data not shown).  379 
  380 
 381 
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SIP is involved in EGF-stimulated expression of COX2 mRNA and protein. 382 
EGF strongly stimulates COX2 expression in primary human amnion (Zakar et al. , 1998) and 383 
myometrial cells (Wouters et al., 2014) leading us to investigate the role of SIP in this effect. In our 384 
study, exposure of myometrial cells to two individual SIP siRNAs in combination resulted in a 385 
decrease in SIP mRNA expression (Figure 4A). Treatment with EGF for 24 h resulted in a significant 386 
increase in COX2 mRNA (2.47 ± 0.52 fold, P < 0.05) and this effect was impaired in siRNA-treated 387 
cells (Figure 4B). Treatment of myometrial cells with two individual SIP siRNAs separately and in 388 
combination resulted in a large decrease in SIP protein expression (Figure 4C and D). COX2 protein 389 
expression was significantly increased after 24 h EGF stimulation (3.86 ± 0.49 fold, P < 0.001, Figure 390 
4C and E), while EGF was unable to significantly increase COX2 expression in cells with SIP 391 
knockdown. The level of EGF-stimulated COX2 protein was also significantly decreased in SIP 392 
knockdown cells when compared to scrambled controls (0.86 ± 0.47 versus 3.86 ± 0.49 fold, P < 393 
0.001, Figure 4E). The mRNA and protein data taken together suggest a role for SIP in EGF-mediated 394 
expression of the COX2.   395 
 396 
EGF-stimulated increases in PGE2 and PGF2α production are SIP-dependent. 397 
To further investigate the role of SIP in PG synthesis, PGE2 and PGF2α release were measured after 398 
EGF treatment and SIP knockdown. EGF was able to stimulate release of PGE2 from primary 399 
myometrial cells after 8 h, and these effects were blocked in cells with SIP knockdown (P < 0.001, 400 
Figure 5A). Modest but significant increases in PGF2α output were measured after 24 h EGF 401 
treatment, and similarly these were reduced after SIP knockdown (P < 0.01, Figure 5B).   402 
 403 
The ERK1/2 signalling pathway is required for both EGF-stimulated SIP phosphorylation and EGF-404 
induced COX2 expression. 405 
EGF treatment caused phosphorylation of SIP in a dose-dependent manner; significant 406 
phosphorylation was detected as low as 1 ng/ml EGF with maximal phosphorylation achieved 407 
between 10 and 25 ng/ml EGF, and phosphorylation decreasing again with 100 ng/ml EGF (Figure 408 
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6A and B). EGF-induced phosphorylation of SIP was transient; significant increases were detected 409 
between 5 and 30 minutes, with maximal phosphorylation at the 15 minute time point and de-410 
phosphorylation occurring by 60 minutes (Figure 6C and D). EGF stimulation resulted in dose- and 411 
time-dependent phosphorylation of ERK1/2 within its activation loop (Figure 6A and C). Since 412 
ERK1/2 is known to play a role in EGF-stimulated COX2 expression (Molnar et al., 1999, Wouters et 413 
al., 2014), its involvement in SIP phosphorylation was investigated. EGF stimulation resulted in 414 
concomitant phosphorylation of both SIP and ERK1/2, and SIP knockdown did not affect EGF-415 
stimulated ERK1/2 phosphorylation (Figure 7A, B and C). The MEK1 inhibitor PD-184352 ablated 416 
ERK phosphorylation in both stimulated and non-stimulated cells (Figure 7C). PD-184352 417 
significantly reduced the level of SIP phosphorylation in EGF-treated cells by 81.5 ± 2.50 % (P < 418 
0.001, n=5, Figure 7B).  Additionally, EGF was no longer able to stimulate expression of COX2 in 419 
PD-184352 treated cells (Figure 7D and E) confirming our previous data (Wouters et al., 2014). 420 
Taken together these results suggest that ERK lies upstream of SIP phosphorylation and both ERK 421 
and SIP contribute to EGF-induced COX2 expression.  422 
 423 
EGF-induced SIP phosphorylation and COX2 induction in fresh human myometrial tissue. 424 
The phosphorylation of SIP in freshly isolated myometrium was investigated alongside EGF-425 
stimulated changes in COX2 expression. EGF was able to significantly stimulate SIP phosphorylation 426 
in myometrial explants (1.94 fold ± 0.26, P < 0.01) which was reduced in cells pre-incubated with the 427 
MEK1 inhibitor PD-184352 (1.94 fold ± 0.26 versus 0.68 fold ± 0.21, P < 0.01, Figure 8A). 428 
Treatment of myometrial tissue with EGF for 24 hours resulted in enhanced protein expression of 429 
COX2 (P < 0.05 for overall effect of EGF), with some effect of MEK1 inhibition (P = 0.053 for 430 
overall effect of PD-184352). 431 
 432 
SIP in involved in regulating production of pro-inflammatory cytokines. 433 
Since COX2 is up-regulated during labour in human myometrium, we expanded our studies on SIP 434 
function to measure the expression of some pro-inflammatory cytokines and chemokines implicated 435 
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in the initiation of labour. Very low levels of IL1B mRNA in primary myometrial cells were detected 436 
relative to IL6, IL8 (CXCL8) and TNF mRNAs (Figure 9A). IL6 and IL8 mRNAs were increased in 437 
response to EGF treatment (1.81 ± 0.35 fold and 2.97 ± 0.88 fold respectively), with SIP knockdown 438 
causing an overall decrease in expression of IL6 and IL8, which was statistically significant (Figures 439 
9C and D, P < 0.05). Despite very low levels of IL1B mRNA, EGF caused modest increases which 440 
were SIP dependent (Figure 9B), while there was no significant effect of EGF or SIP knockdown on 441 
TNF mRNA expression (Figure E).  442 
 443 
SIP is involved in negatively regulating the activity of multiple TFs. 444 
To test the hypothesis that SIP mediates its effects on COX2, IL6 and IL8 expression by modulating 445 
TF activity, we carried out a profile of TF activation in SIP knockdown cells relative to cells 446 
transfected with scrambled siRNA. A total of 47 TFs were assessed by their ability to bind their 447 
consensus DNA sequences using a commercially available array. The effect of SIP knockdown on TF 448 
activity ranged from a mean ± SEM of 0.63 ± 0.18 to 14.47 ± 3.96 fold (n=3, Supplementary Table 449 
IV), however there were considerable variations in TF activity between the three experiments 450 
conducted.  TFs with the greatest change in activity after SIP knockdown are shown in Figure 10; 451 
reduction in SIP expression resulted in increased activity of  serum response factor (SRF), signal 452 
transducer and activator of transcription (STAT) 2, YY1 TF (YY1), SMAD family (SMAD), nuclear 453 
receptor subfamily 1 group I member 3 (NR1I3), glucocorticoid receptor/progesterone receptor 454 
(GR/PR), NFKB1, STAT5, CCAAT/enhancer binding protein zeta (CEBPZ); and early growth 455 
response (EGR), although only two of these were statistically significant. Large and significant 456 
increases in SRF (14.47 ± 3.96 fold, P < 0.001) and YY1 (12.84 ± 6.37, P < 0.05) with SIP 457 
knockdown suggest that SIP functions to negatively regulate the activity of these TFs in human 458 
myometrial cells.  459 
  460 
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Discussion 461 
This is the first description of SIP expression and function in uterine tissues. SIP was identified in 462 
FSK-stimulated human myometrial cell lysates by MS. The expression of SIP protein was high in 463 
myometrium and amnion/chorion/decidua (parietalis) but low in placenta and decidua basalis. EGF 464 
caused ERK-dependent phosphorylation of SIP in myometrial cells at a site, or sites, detectable using 465 
antibody 44-1085G which is actually marketed for detection of pMYLK.  This antibody, in 466 
combination with siRNA knockdown of SIP as a negative control, has proved a valuable tool for 467 
measuring SIP phosphorylation. Targeted siRNA knockdown of SIP has also revealed that SIP is 468 
required for EGF-stimulated COX2 expression and resulting PG release, in addition to expression of 469 
IL6 and IL8 mRNAs in human myometrium. 470 
 471 
SIP binds to the steroid receptor co-activator protein SRC-1 (NCOA1), thereby sequestering SRC-1 in 472 
the cytoplasm and negatively regulating estrogen-dependent transcription in a breast cancer cell line 473 
(Zhang et al., 2007), however there is no published information about the functional roles of SIP in 474 
uterine tissues.  We screened genes that are potentially regulated by steroid hormones, and the steroid 475 
receptor coactivators, SRC1 (NCOA1) and SRC2 (NCOA2) in myometrium. This revealed that SIP 476 
removal decreases expression of COX2 mRNA. Myometrial COX2 expression can be stimulated by a 477 
variety of pro-inflammatory cytokines, and by OXT, PGs and EGF (Chen et al., 2012, Molnar et al., 478 
1999, Phillips et al., 2011, Sooranna et al., 2004, Wouters et al., 2014), and since EGF was capable of 479 
phosphorylating SIP we focussed on determining the role of SIP in EGF-induced myometrial COX2 480 
expression. SIP depletion by siRNA decreased the ability of EGF to stimulate COX2 mRNA and 481 
COX2 protein expression.  Importantly, reduction of SIP also inhibited PGE2 and PGF2α production in 482 
response to EGF. To investigate the signalling pathways upstream of SIP, pharmacological inhibition 483 
of MEK1/ERK signalling was achieved with PD-184352.  ERK1/2 activity was required both for the 484 
phosphorylation of SIP and up-regulation of COX2 protein expression in response to EGF. Moreover, 485 
SIP knockdown did not affect the ability of EGF to activate ERK1/2, placing SIP downstream of 486 
ERK1/2 activation and upstream of COX2 regulation.   The data replicate previous observations that 487 
EGF-mediated COX2 expression requires ERK1/2 signalling (Wouters et al., 2014), and demonstrate 488 
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the functional involvement of SIP in this pathway. No effect of SIP knockdown on pro-inflammatory 489 
cytokine (IL1B)-induced COX2 expression was observed (data not shown) however since the 490 
magnitude of IL1B-induced COX2 is so large, alternative pathways such as NFKB may dominate 491 
over SIP involvement (Wouters et al., 2014). Since uterine COX2 is a key regulator of PG synthesis 492 
at labour, we expanded our study on SIP to investigate its regulation of other pro-labour mediators. 493 
SIP was positively involved in EGF-stimulated myometrial IL6 and IL8 mRNA expression, which 494 
have both been shown to increase with labour (Osmers et al., 1995, Tattersall et al., 2008). Taken 495 
together, these data support our hypothesis that SIP plays a role in regulating labour-related gene 496 
expression in human myometrium. While no difference in SIP protein expression was seen between 497 
non-labouring myometrium and that taken after labour induction, this does not exclude the possibility 498 
of transient changes in SIP expression at the onset of spontaneous labour. Moreover, the functional 499 
significance of the relatively high level of SIP expression in amnion/chorio-decidua in pregnancy 500 
needs to be investigated. 501 
 502 
Further investigations into the mechanism of action for SIP led us to demonstrate that SIP expression 503 
is negatively associated with the activity of several TFs, in particular SRF and YY1. SRF and YY1 504 
can both bind to the serum response element (SRE) and the observation that YY1 enhances binding of 505 
SRF to SRE (Natesan et al., 1995) highlights a relevant pathway that is potentially regulated by SIP. 506 
Since ERK signalling results in phosphorylation of SIP and also phosphorylation of SRF (Rivera et 507 
al., 1993) the functional interaction between SIP and SRF is likely to be a fruitful area of research. It 508 
is possible that SIP may positively or negatively affect TF activity by binding and sequestering either 509 
co-repressors or co-activators in the cytoplasm (Ramot et al. , 2014, Zhang et al. , 2007), although the 510 
identity of such factors remains to be determined. 511 
 512 
Two sites of SIP phosphorylation detectable only after EGF stimulation have been identified during 513 
MS experiments, namely serine 323 and serine 375. Serine 323 lies within a medium stringency 514 
consensus motif for both cyclin-dependent kinase (CDK) 1 and CDK5 phosphorylation. Serine 375 515 
lies within a medium stringency consensus motif for ERK1, glycogen synthase kinase 3, CDK1 and 516 
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CDK5 phosphorylation, and a low stringency consensus motif for 14-3-3 zeta/delta binding 517 
(Obenauer et al. , 2003). We propose that phosphorylation of SIP is required for its role as a 518 
transcriptional regulator, and identification of these sites suggests that ERK1/2 may directly 519 
phosphorylate SIP at serine 375. However more studies are required to verify the specific sites of 520 
phosphorylation, the protein kinases involved and their functional significance.   521 
 522 
EGF is released by the fetus into the amniotic fluid during pregnancy and levels increase rapidly in 523 
late pregnancy (Hofmann and Abramowicz, 1990, Varner et al. , 1996). While some studies have 524 
demonstrated no effect of labour on amniotic EGF levels (Hofmann and Abramowicz, 1990), others 525 
have shown that EGF increases with labour (Romero et al. , 1989) and in cases of premature rupture 526 
of the membranes with and without underlying infection (Shobokshi and Shaarawy, 2002).  EGF 527 
exerts its function by binding to the EGF receptor (EGFR, the first described member of the ErbB 528 
tyrosine kinase family). EGF and EGFR mRNAs have both been detected in human myometrial cells 529 
(Yeh et al. , 1991). Binding of EGF to EGFR stimulates its tyrosine kinase activity leading to EGFR 530 
auto-phosphorylation (Honegger et al. , 1990), resulting in recruitment of adaptor proteins and 531 
activation of signalling pathways such as ERK1/2, phospholipase C gamma, PKC, 532 
phosphatidylinositol 3-kinase - Akt and NFKB (Jorissen et al. , 2003).  In parallel to amniotic fluid 533 
EGF levels, COX2 in fetal membranes increases during gestation and further with labour (Slater et 534 
al., 1999a), and in myometrium with labour at term and preterm (Slater et al., 1999b).  The 535 
subsequent intra-uterine release of PGs facilitates labour by coordinating membrane rupture, 536 
myometrial contractions and cervical ripening. It is tempting to speculate that EGF-mediated 537 
increases in COX2 and PG release could be important during the initiation of labour, particularly in a 538 
supporting role to the action of OXT or inflammatory cytokines.  539 
 540 
In summary, we have found that an antibody marketed for detection of pMYLK actually provides a 541 
unique tool for detection of pSIP. Exploiting this serendipitous observation we have made several 542 
novel findings pertinent to myometrial cell signalling (Figure 11): a) that SIP is expressed in human 543 
myometrium and fetal membranes, b) that EGF causes ERK-dependent phosphorylation of SIP, c) 544 
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that ERK and SIP are involved in EGF-stimulated COX2 expression, and d) that SIP regulates EGF-545 
dependent release of PGs. We suggest that SIP may be directly phosphorylated and regulated by ERK 546 
and propose that SIP regulates the activity of multiple TFs, providing novel mechanisms for 547 
modifying gene expression. These findings increase our understanding of the complex mechanisms 548 
regulating the transition into human labour involving increased PG production, and could lead to the 549 
development of new, targeted drugs for the control of uterine activation in the management of preterm 550 
labour.  551 
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Figure 1. Steroid receptor co-activator interacting protein (SIP) is phosphorylated in human 
myometrial cells by epidermal growth factor (EGF) and forskolin (FSK). 
Cultured myometrial cells were transfected with non-targeting siRNA (-) or siRNA targeted to SIP (+) 
before being stimulated with oxytocin (OXT; 10nM, 5 mins), EGF (25 ng/ml, 15 mins), carbachol 
(CCh; 200 µM, 5 mins) or FSK (10 µM, 15 mins). Cells lysates were resolved by SDS-PAGE and 
immunoblotting carried out for SIP and pSIP, the latter measured using antibody 44-1085G raised 
against phosphorylated myosin light chain kinase (pMYLK). The pSIP bands were reduced in SIP 
siRNA samples confirming their identity.  
 
Figure 2. SIP is predominantly expressed in human amnion/chorion/decidua and myometrium, 
with poor expression in placenta and decidua basalis. 
Tissues were collected from women not in labour undergoing caesarean section at term and snap 
frozen until homogenisation as per Methods. A, tissue homogenates were resolved by SDS-PAGE and 
immunoblotting was carried out for SIP and RhoGDI (loading control). B, SIP levels were quantified 
by densitometry and standardised over multiple gels using an internal control (a mixture of all tissue 
lysates). Data were further normalised to the level of RhoGDI. PLA, placenta; DEC, decidua basalis; 
ACD, amnion/chorion/decidua parietalis; MYO, myometrium. Data were analysed using one-way 
analysis of variance (ANOVA) and Tukey's post-hoc tests; * P < 0.05 for the comparisons between 
PLA or DEC and ACD, and ** P < 0.01 for the comparisons between PLA or DEC and MYO.  
Figure 3. Myometrial SIP expression decreases with pregnancy and is unchanged after induction 
of labour. 
Myometrium was collected from women undergoing non-pregnant hysterectomy (NP, n=4), 
caesarean section without labour before 37 weeks (PNIL, n=6) or at term (TNIL, n=6), and after 
induction of labour at term (IOL, n=4). Tissues were and snap frozen until homogenisation as 
described in Methods. A, tissue homogenates were resolved by SDS-PAGE and immunoblotting was 
carried out for SIP and RhoGDI (loading control), a representative blot is shown. Samples were from 
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the same gel but discontinuous lanes (horizontal line). B, SIP levels were quantified by densitometry 
and standardised over multiple gels using an internal control (a mixture of all tissue lysates). Data 
were further normalised to the level of RhoGDI and analysed using one-way ANOVA and Bonferroni 
post-hoc tests; * P < 0.05 for the comparisons between NP and PNIL, TNIL or IOL.  
 
 
 
Figure 4. SIP in involved in EGF-stimulated increases in COX2 mRNA and protein. 
Primary myometrial cells were transfected with scrambled siRNA (SCR) or siRNA targeting SIP; 
siRNA 1 (SIP1), siRNA 2 (SIP2) or a combination of both siRNAs (S1/2). Two days following 
transfection cells were left as non-stimulated controls (CON) or treated with 25 ng/ml EGF for 24 h. 
RT-qPCR for SIP (A) and COX2 (B) was performed, data were normalised using ribosomal 18S 
(RNA18S5) and RNA polymerase (POLR2A) and then expressed as fold change relative to SCR, 
CON. Statistics were performed using a paired Student's T test (A) or 2-way ANOVA and Bonferroni 
post-hoc tests (B); $, P < 0.001 for knockdown of SIP mRNA, n=6; * P < 0.05 for effect of EGF in 
SCR, n=3; ns, not significant for effect of EGF in S1/2. C, immunoblotting for SIP, COX2 and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was performed and SIP knockdown in non-
stimulated cells was quantified (D, $, P < 0.001, n=8). C, COX2 levels were quantified, normalised to 
GAPDH levels then expressed as fold change compared to SCR, CON. Statistics were performed 
using a paired Student's T test (A) or 2-way ANOVA and Bonferroni post-hoc tests (B); P = 0.007 for 
overall effect of SIP siRNA; $, P < 0.001 for effect of EGF in SCR and effect of S1/2 siRNA in EGF-
stimulated cells; ns, not significant for effect of EGF with S1/2 siRNA, n = 4. 
Figure 5. EGF-stimulated increases in PGE2 and PGF2α production are dependent on SIP. 
Primary human myometrial cells were transfected with scrambled siRNA (SCR) or 2 separate 
siRNAs targeting SIP (SIP). Two days following transfection cells were not treated or treated with 25 
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ng/ml EGF for 4, 8 or 24 h. PGE2 metabolites and PGF2α were assayed in the culture media using 
commercially available kits as per methods. Statistics were performed using 2-way ANOVA with 
repeated measures and Bonferroni post-hoc tests *, P < 0.05, ** P < 0.01 and  ***, P < 0.001 for the 
effect of EGF at 8 or 24 h relative to non-stimulated; a , P < 0.05, b , P < 0.01 and c , P < 0.001 for the 
effect of SIP siRNA at 8 or 24 h relative to SCR.  
Figure 6. EGF phosphorylates SIP in a dose- and time-dependent manner. 
Primary human myometrial cells grown until confluent were serum starved for 4 hours before being 
treated. A and B, cells were treated with increasing concentrations of EGF as shown for 15 min. B and 
D, cells were treated with 25 ng/ml EGF for increasing time as shown. Immunoblotting was carried 
out for pSIP, SIP, pERK and ERK; pSIP was quantified by densitometry, normalised to total SIP 
levels and expressed as a percentage of maximal phosphorylation. Statistics were performed using 
repeated-measures ANOVA and Dunnett’s post-hoc tests, *, P < 0.01 relative to non-stimulated; n = 
5. 
 
Figure 7. The ERK1 pathway is required for both EGF-stimulated SIP phosphorylation and EGF-
induced COX2 expression. 
A, B and C, primary human myometrial cells transfected with non-targeting siRNA or siRNA 
targeted to SIP. They were subsequently pre-treated with PD-184352 (PD; 10µM for 30 min) or 
vehicle control (VEH, 0.1% DMSO) before remaining non-stimulated (CON) or treated with 25 
ng/ml EGF for 15 min.  A, Immunoblotting for pSIP, SIP, pERK1/2 and ERK1/2 was performed. 
Samples were loaded on a single gel but were in discontinuous lanes (solid line) B, pSIP levels were 
quantified and normalised to the level of total SIP, and expressed as a percentage of the EGF-
stimulated value. C, pERK1/2 levels were quantified and normalised to the levels of total ERK1/2 and 
expressed as a percentage of the EGF-stimulated value. Statistics were performed using 2-way 
ANOVA and Bonferroni post-hoc tests, $, P < 0.001; #, P < 0.01; *, < P < 0.05; n = 5. D, cells were 
pre-treated with or without PD-184352 as above and subsequently stimulated with or without 25 
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ng/ml EGF for 24 h. Immunoblotting was carried out for COX2 and GAPDH, samples were loaded on 
a single gel but were in discontinuous lanes (solid line) E, COX2 levels were quantified, normalised 
by levels of GAPDH and expressed as a percentage of the EGF-stimulated value. Statistics were 
performed using 2-way ANOVA and Bonferroni post-hoc tests; #, P < 0.01; NS, non-significant; n = 
3. 
 
Figure 8. EGF-induced SIP phosphorylation and COX2 expression in fresh human myometrial 
tissue. 
Myometrial explants in culture were treated for either 15 min (A) or 24 h (B) with EGF, following 
pre-treatment for 30 min with PD-184352 (PD) or DMSO vehicle control (VEH). After snap freezing 
and homogenising the muscle, proteins were resolved by SDS-PAGE and immunoblotting carried out 
for pSIP, SIP, COX2 or RhoGDI (loading control). The levels of pSIP and COX2 were quantified by 
densitometry, normalised to the level of SIP and RhoGDI respectively, and expressed as fold change 
relative to CON, VEH. Statistics were performed using 2-way ANOVA and Bonferroni post hoc tests; 
#, P < 0.01; n=4 (A). *, P < 0.05 for the overall effect of EGF, n=4 (B). 
 
Figure 9. SIP is involved in regulating production of pro-inflammatory cytokines. 
Relative levels of IL1B, IL6, IL8 (CXCL8) and TNFα mRNA in non-stimulated primary myometrial 
cells were determined by RT-pPCR (A). Myometrial cells were transfected with scrambled siRNA 
(SCR) or a combination of two SIP siRNAs (SIP). Two days following transfection cells were left as 
non-stimulated controls (CON) or treated with 25 ng/ml EGF for 24 h. RT-qPCR for IL1B (B), IL6 
(C), IL8 (CXCL8) (D) or TNF (E) was performed, data were normalised using RNA18S5 and POLR2A 
and then expressed as fold change relative to SCR, CON. Statistics were performed using 2-way 
ANOVA and Bonferroni post-hoc tests; * P < 0.05 and ** P < 0.01 for overall effect of EGF or 
overall effect of SIP siRNA for IL6 and IL8, n=4. 
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Figure 10. SIP is involved in negatively regulating the activity of multiple transcription factors 
(TFs). 
Primary human myometrial cells were transfected with scrambled siRNA (SCR) or a combination of 
two SIP siRNAs (SIP). The activation of 47 TFs was assayed in nuclear extracts by their ability to 
bind their consensus DNA sequence, using a commercially available array, as per methods. Data are 
presented as fold activation in SIP relative to SCR (mean ± SEM, n = 3) and the top 10 TFs with the 
greatest change are shown. *** P < 0.001 and * P < 0.05 using one-sample t-tests against a constant 
of 1. SRF, serum response factor; STAT2, signal transducer and activator of transcription 2; YY1, 
YY1 transcription factor; SMAD, SMAD family; NR1I3, Nuclear receptor subfamily 1 group I 
member 3; GR/PR, glucocorticoid receptor/progesterone receptor; NFKB, nuclear factor kappa B 1; 
STAT5, signal transducer and activator of transcription 5; CEBPZ, CCAAT/enhancer binding protein 
zeta; EGR, early growth response. 
 
Figure 11. Summary pathways for myometrial SIP function. 
Proposed pathways for EGF-mediated and SIP-dependent COX2 expression and PG release. SIP 
knockdown inhibits expression of COX2, IL6, IL8 and PG release. Conversely SIP knockdown 
causes increased activity of several TFs including SRF and YY1. Dashed lines represent additional 
possible pathways. Through these pathways SIP is likely to participate in the complex mechanism of 
human parturition. 
Supplementary figure 1. Immunoprecipitation with pMYLK (44-1085G) antibody for identification 
of SIP. 
Myometrial cells were non-stimulated (CON) or stimulated with 10 µM FSK for 15 mins and 
subsequently lysed as per Methods.  Immunoprecipitation of both lysates was carried out using a 
pMYLK antibody (44-1085G); immunoprecipitates (IPs) and whole cell lysates (WCL) were run on 
two SDS-PAGE gels in parallel. One gel was used for immunoblotting using the 44-1085G antibody 
(A) and re-probed for MYLK (B) and the second was silver stained (C). After overlay of the 44-
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1085G immunoblot (IB) and silver stained gel, a gel slice equivalent to the ~ 100 kDa 44-1085G 
immunogen (highlighted in a box on the 44-1085G blot and gel) was cut from the silver stained gel. 
Bands referred to in Results are indicated by arrows numbered 1-5. 
 
 
  
36 
 
 
Target Accession # Forward primer (5’–3’) Position Reverse primer (5’–3’) Position 
RNA18S5  NR_003286 ATGGCCGTTCTTAGTTGGTG 1332 CGCTGAGCCAGTCAGTGTAG 1548 
POLR2A  NM_000937 GCACCACGTCCAATGACATTG 4453 GTGCGGCTGCTTCCATAAGC 4719 
COX2 NM_000963 CAAAGGTAAAAAGCAGCTTCCT 590 CTGGGGATCAGGGATGAACT 671 
SIP  NM_015493 CCCAGAAGTTCCTGCCGAAT 1333 GACTCTTGGGAGGCTGCTTG 1457 
IL1B  NM_000576 CAACAGGCTGCTCTGGGATTC 28 AGTCATCCTCATTGCCACTGT 131 
IL6 NM_000600 TGGATTCAATGAGGAGACTTGC 433 GGGTCAGGGGTGGTTATTGC 608 
IL8 
(CXCL8) 
NM_000584 TGCAGCTCTGTGTGAAGGTG 201 GGGGTGGAAAGGTTTGGAGT 272 
TNF NM_000594 TGGGATCATTGCCCTGTGAG 859 GGTGTCTGAAGGAGGGGGTA 931 
 
Table I. Primer pairs for quantitative RT-PCR. 
The position of each primer’s 5’-terminal nucleotide within the mRNA is indicated. RNA18S5, 18S 
ribosomal RNA; POLR2A, RNA polymerase II subunit B1; COX2, cyclooxygenase 2; SIP, steroid 
receptor coactivator interacting protein; IL1B, interleukin 1B; IL6, interleukin 6; IL8, interleukin 8; 
CXCL8, chemokine (C-X-C Motif) ligand 8; TNF, tumor necrosis factor. 
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Supplementary tables and legends 
Supplementary table I 
 
 
 
 
 
 
 
 
Supplementary table I. Mass spectrometry (MS) identification of steroid receptor co-activator 
interacting protein (SIP or KANK2) from 44-1085G immunoprecipitates (IPs), n=3.  
A gel slice corresponding to the 100 kDa ‘pMYLK’ immunogen was subjected to in-gel digestion, 
peptide fractionation and tandem mass spectrometry analysis carried out on a LTQ-Orbitrap Velos 
mass spectrometer (see Methods).  The raw data files were processed using Proteome Discoverer 
software v1.2 with searches performed against the UniProt Human database using the SEQUEST 
algorithm.  The reverse database search option was enabled and all peptide data was filtered to satisfy 
false discovery rate (FDR) of 5%. KN motif and ankyrin repeat domain-containing protein 2 
(KANK2) was the top hit when ranked by protein score after exclusion of keratin. Percentage 
sequence coverage, # peptide spectrum matches (PSMs) and # peptides matched are shown. 
 
Supplementary table II 
 
Sequence Modifications 
Phosphorylation 
site 
Probability XCorr m/z [Da] MH+ [Da] 
AQSLEPYGTGLR S3(Phospho) Serine 356 2.24 2.89 686.32 1371.64 
VPSVAEAPQLRPAGTAAAK S3(Phospho) Serine 548 24.62 3.08 957.49 1913.99 
ALAMPGRPESPPVFR 
M3(Oxidation) 
S10(Phospho) 
Serine 375 31.55 2.94 852.92 1704.83 
QADPQPQAWPPPDSPVRVDTVR S14(Phospho) Serine 323 1.37 3.43 846.07 2536.21 
 
Supplementary table II. Peptides from SIP (KANK2) phosphorylated within 44-1085G IPs from 
forskolin-treated cells. 
Expt # Accession Description 
Gene 
Name 
Coverage 
(%) 
# PSMs # Peptides Score 
1 Q63ZY3 KN motif and 
ankyrin repeat 
domain-containing 
protein 2 
KANK2 20.45 98 10 564.59 
2 Q63ZY3 KN motif and 
ankyrin repeat 
domain-containing 
protein 2 
KANK2 47.36 141 32 710.33 
3 Q63ZY3 KN motif and 
ankyrin repeat 
domain-containing 
protein 2 
KANK2 21.62 42 15 277.65 
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Following tandem mass spectrometry on a LTQ-Orbitrap Velos mass spectrometer (see Methods), the 
raw data files were processed using Proteome Discoverer software v1.2. Searches of the UniProt 
Human database using the SEQUEST algorithm included phosphorylation of serine, threonine and 
tyrosine as variable modifications. Specific phospho-peptides identified in a representative experiment 
are shown with the phospho-amino acid highlighted in bold, these were all identified at < 1 % FDR. 
Proteome Discoverer Probability Score, XCorr, mass to charge ratio (m/z) in daltons (Da) and 
precursor ion mass (MH+) of the individual peptides are shown. 
 
Supplementary table III 
 
Sequence Modifications 
Phosphorylation 
site 
EGF 
MH+ [Da] 
Probability Xcorr m/z [Da] 
ALAMPGRPESPPVFR 
M4(Oxidation) 
S10(Phospho) 
Serine 375 7.22 3.26 860.91 1720.81731 
QADPQPQAWPPPDSPVRVDTVR S14(Phospho) Serine 323 21.80 3.90 846.07 2536.19217 
 
Supplementary table III. SIP (KANK2) peptides within SIP IPs phosphorylated in epidermal growth 
factor (EGF)-treated cells and absent in non-stimulated samples. 
SIP (antibody ab99351) and control (normal rabbit IgG) IPs were performed from non-stimulated or 
EGF-stimulated myometrial cell lysates.  IPs were resolved by gel electrophoresis, and subjected to 
in-gel digestion, peptide fractionation and tandem mass spectrometry analysis carried out on a LTQ-
Orbitrap Velos mass spectrometer (see Methods).  The raw data files were processed using Proteome 
Discoverer software v1.4 with searches performed against the UniProt Human database using the 
SEQUEST algorithm, including phosphorylation of serine, threonine and tyrosine as variable 
modifications. Peptides associated with SIP (KANK2) were filtered at 1% FDR and to select 
phosphorylated peptides present only in EGF-stimulated SIP IPs (absent in the non-stimulated SIP IP 
and control IPs). The two resulting phospho-peptides are shown with the phosphorylation site in SIP 
indicated; Proteome Discoverer Probability Score, XCorr, m/z and MH+ of the individual peptides are 
shown. 
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Supplementary table IV 
TF Mean ± SEM TF Mean ±  SEM 
SRF 14.47 ± 3.96 *** NF1 1.22 ± 0.56 
STAT2 14.10 ± 8.40 NR1I2 1.20 ± 0.53 
YY1 12.84 ± 6.37 * TR 1.14 ± 0.49 
SMAD 8.81 ± 2.52 HNF4 1.08 ± 0.33 
NR1I3 5.48 ± 4.90 Pax-5 1.03 ± 0.30 
GR/PR 5.26 ± 3.28 STAT1 1.02 ± 0.65 
NFKB 4.90 ± 2.38 NF-E2 1.02 ± 0.58 
STAT5 4.32 ± 2.11 SATB1 1.02 ± 0.41 
CEBPZ 4.26 ± 2.15 PPAR 1.00 ± 0.48 
EGR 4.06 ± 1.99 TCF/LEF 0.99 ± 0.35 
p53 3.35 ± 1.80 Ets 0.99 ± 0.34 
STAT3 2.70 ± 1.09 ER 0.98 ± 0.34 
SP1 2.53 ± 1.61 Pbx1 0.94 ± 0.37 
E2F1 1.91 ± 0.63 C\EBP 0.94 ± 0.26 
CREB 1.89 ± 0.75 CDP 0.91 ± 0.59 
NFAT 1.85 ± 1.29 Pit 0.89 ± 0.56 
IRF 1.65 ± 0.59 GAS/ISRE 0.87 ± 0.25 
AP-1 1.53 ± 0.53 FAST-1 0.85 ± 0.25 
TBP 1.46 ± 0.52 Myb 0.84 ± 0.24 
OCT4 1.44 ± 0.52 ATF-2 0.80 ± 0.32 
MEF2 1.42 ± 0.35 HIF 0.79 ± 0.56 
GATA 1.34 ± 0.47 AP-2 0.72 ± 0.28 
Myc-MAX 1.25 ± 0.78 AR 0.63 ± 0.18 
STAT6 1.24 ± 0.60     
 
Supplementary table IV. Transcription factor (TF) activation after SIP knockdown. 
Primary myometrial cells were transfected with scrambled siRNA (SCR) or a combination of two SIP 
siRNAs (SIP). The activation of 47 TFs was assayed in nuclear extracts by their ability to bind their 
consensus DNA sequence, as per methods. Data are presented as fold activation in SIP relative to 
SCR (mean ± SEM, n = 3), and one-sample t-tests were performed against a constant of 1; *** P < 
0.001, * P < 0.05. AP1, Activator protein 1 (JUN/FOS); AP2, Activator protein 2; AR, Androgen 
receptor; ATF2, activating transcription factor 2; Brn-3, POU domain, class 4, transcription factor 1;  
C/EBP, CCAAT/enhancer binding protein alpha; CEBPZ, CCAAT/enhancer binding protein 
(C/EBP), zeta; CDP, CCAAT displacement protein; CREB, cAMP responsive element binding 
protein 1; E2F1, E2F transcription factor 1; EGR, Early growth response; ER, Estrogen receptor;  Ets, 
v-ets erythroblastosis virus E26 oncogene homolog 1; FAST-1, Forkhead box H1; GAS/ISRE, IFN-
stimulated response element; GATA, GATA transcription factor; GR/PR, Glucocorticoid 
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receptor/Progesterone receptor; HIF, Hypoxia inducible factor; HNF4, Hepatocyte nuclear factor 4; 
IRF, Interferon regulatory factor; MEF2, Myocyte enhancer factor 2; Myb, v-myb myeloblastosis 
viral oncogene homolog; Myc-Max, v-myc myelocytomatosis viral oncogene homolog (avian); NF1, 
Nuclear factor 1; NFAT Nuclear factor of activated T-cells; NF-E2, Nuclear factor (erythroid-derived 
2); NFKB, nuclear factor of kappa B; NR1I, nuclear receptor subfamily 1, group I; OCT4, POU class 
5 homeobox 1; p53, Tumor protein p53; Pax-5, Paired box 5; Pbx1, Pre-B cell leukemia transcription 
factor-1; Pit, Pituitary specific transcription factor 1; PPAR, Peroxisome proliferator-activated 
receptor; PXR, Pregnane X receptor; SMAD, SMAD family; SP1, SP1 transcription factor, SRF, 
Serum response factor; SATB1, Special AT-rich sequence binding protein 1; STAT, Signal transducer 
and activator of transcription; TBP, TATA box binding protein; TCF/LEF, Runt-related transcription 
factor 2; TR, Thyroid hormone receptor; YY1, YY1 transcription factor. 
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